Medicinova Inc SEC filings MNOV
Medicinova Inc has 879 filings in SEC EDGAR's recent list, going back to Apr 8, 2003. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Filing | Apr 20, 2026 | — |
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| EFFECT | Filing | Sep 6, 2022 | — |
| CORRESP | Letter to the SEC | Sep 1, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 31, 2022 | — |
| EFFECT | Filing | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 8, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2021 | — |
| EFFECT | Filing | Aug 22, 2019 | — |
| CORRESP | Letter to the SEC | Aug 20, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2017 | — |
| EFFECT | Filing | Oct 2, 2017 | — |
| CORRESP | Letter to the SEC | Sep 27, 2017 | — |
| EFFECT | Filing | Dec 9, 2016 | — |
| EFFECT | Filing | Aug 29, 2016 | — |
| CORRESP | Letter to the SEC | Aug 25, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2015 | — |
| 8-A12G/A | Form 8a amendment | Mar 21, 2014 | — |
| EFFECT | Filing | Dec 3, 2012 | — |
| CT ORDER | Filing | Sep 26, 2011 | — |
| EFFECT | Filing | Dec 16, 2009 | — |
| 425 | Form 8-k | Dec 15, 2009 | — |
| CORRESP | Letter to the SEC | Dec 14, 2009 | — |
| 425 | Form 8-k | Dec 9, 2009 | — |
| UPLOAD | Letter from the SEC | Nov 23, 2009 | — |
| EFFECT | Filing | Nov 18, 2009 | — |
| 425 | Form 8-k | Nov 17, 2009 | — |
| CORRESP | Letter to the SEC | Nov 17, 2009 | — |
| UPLOAD | Letter from the SEC | Nov 9, 2009 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2009 | — |
| 425 | Form 8-k | Sep 4, 2009 | — |
| 425 | Form 8-k | Aug 24, 2009 | — |
| 425 | Form 8-k | Jun 25, 2009 | — |
| CT ORDER | Filing | May 14, 2009 | — |
| 425 | Form 8-k | Mar 24, 2009 | — |
| 425 | Form 8-k | Mar 20, 2009 | — |
| 425 | Form 8-k | Mar 12, 2009 | — |
| 425 | Form 8-k | Feb 9, 2009 | — |
| 425 | Form 8-k | Dec 23, 2008 | — |
| CERTNAS | Auto-generated paper document | Dec 6, 2006 | — |
| 8-A12B | Form 8-a12b | Dec 5, 2006 | — |
| 8-A12G | Form 8-a12g | Nov 29, 2006 | — |
| EFFECT | Filing | Nov 14, 2006 | — |
| PRER14A | Amendment no. 1 to preliminary proxy statement | Aug 18, 2006 | — |
| CORRESP | Letter to the SEC | Aug 18, 2006 | — |
| CORRESP | Letter to the SEC | Aug 18, 2006 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2006 | — |
| 8-A12G | Form 8-a for medicnova, inc. | Jan 26, 2005 | — |
| CORRESP | Letter to the SEC | Jan 25, 2005 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2004 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2004 | — |
| REGDEX/A | Auto-generated paper document | Sep 20, 2004 | — |
| REGDEX | Auto-generated paper document | Sep 13, 2004 | — |
| REGDEX | Auto-generated paper document | Apr 8, 2003 | — |
Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNOV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1226616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.